{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:55:12Z","timestamp":1781297712513,"version":"3.54.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T00:00:00Z","timestamp":1588982400000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.actbio.2019.03.048","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T12:50:29Z","timestamp":1553777429000},"page":"300-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy"],"prefix":"10.1016","volume":"90","author":[{"given":"Zhuoya","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieni","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Moharil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binfeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6230","key":"10.1016\/j.actbio.2019.03.048_b0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.actbio.2019.03.048_b0010","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.actbio.2019.03.048_b0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.actbio.2019.03.048_b0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.actbio.2019.03.048_b0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.actbio.2019.03.048_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2015.10.009","article-title":"Immune suppressive mechanisms in the tumor microenvironment","volume":"39","author":"Munn","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"24","key":"10.1016\/j.actbio.2019.03.048_b0035","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 inhibitors: from bench to bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.actbio.2019.03.048_b0040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrc1613","article-title":"Immunotherapy and chemotherapy\u2014a practical partnership","volume":"5","author":"Lake","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2019.03.048_b0045","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","author":"Holmgaard","year":"2013","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.actbio.2019.03.048_b0050","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nm1196","article-title":"Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy","volume":"11","author":"Muller","year":"2005","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.actbio.2019.03.048_b0055","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2019.03.048_b0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.actbio.2019.03.048_b0065","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrc1613","article-title":"Immunotherapy and chemotherapy\u2013a practical partnership","volume":"5","author":"Lake","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"Suppl. 5","key":"10.1016\/j.actbio.2019.03.048_b0070","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.actbio.2019.03.048_b0075","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.actbio.2018.06.010","article-title":"A multi-functional polymeric carrier for simultaneous positron emission tomography imaging and combination therapy","volume":"75","author":"Sun","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2019.03.048_b0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jconrel.2017.05.006","article-title":"Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy","volume":"258","author":"Sun","year":"2017","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.actbio.2019.03.048_b0085","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1166\/jbn.2017.2475","article-title":"Recent progress in functional micellar carriers with intrinsic therapeutic activities for anticancer drug delivery","volume":"13","author":"Qu","year":"2017","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.actbio.2019.03.048_b0090","doi-asserted-by":"crossref","first-page":"13443","DOI":"10.1038\/ncomms13443","article-title":"An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy","volume":"7","author":"Chen","year":"2016","journal-title":"Nat. Commun."},{"issue":"15","key":"10.1016\/j.actbio.2019.03.048_b0095","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1158\/0008-5472.CAN-07-1872","article-title":"Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2, 3-dioxygenase inhibitory compound D-1-methyl-tryptophan","volume":"67","author":"Metz","year":"2007","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.actbio.2019.03.048_b0100","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1021\/jm2006782","article-title":"Tryptophan 2, 3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl) ethenyl) indoles as potential anticancer immunomodulators","volume":"54","author":"Dolu\u0161i\u0107","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.actbio.2019.03.048_b0105","article-title":"Selective inhibition of indoleamine 2, 3-dioxygenase (IDO1) effectively regulates mediators of anti-tumor immunity","author":"Liu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2019.03.048_b0110","first-page":"25","article-title":"Indoximod modulates AhR-driven transcription of genes that control immune function","volume":"1","author":"Brincks","year":"2018","journal-title":"Ratio"},{"issue":"12","key":"10.1016\/j.actbio.2019.03.048_b0115","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4161\/cbt.12.12.18142","article-title":"Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2, 3-dioxygenase","volume":"12","author":"Chang","year":"2011","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.actbio.2019.03.048_b0120","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1600-065X.2008.00604.x","article-title":"Twelve immunotherapy drugs that could cure cancers","volume":"222","author":"\u2018Mac\u2019Cheever","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.actbio.2019.03.048_b0125","article-title":"Indoleamine 2, 3-dioxygenase expression in human cancers: clinical and immunologic perspectives","volume":"2","author":"Godin-Ethier","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.actbio.2019.03.048_b0130","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.4161\/onci.21716","article-title":"IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan","volume":"1","author":"Metz","year":"2012","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.actbio.2019.03.048_b0135","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00262-014-1549-4","article-title":"Indoleamine 2, 3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer","volume":"63","author":"Prendergast","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.actbio.2019.03.048_b0140","article-title":"Phase 2 trial of the indoleamine 2, 3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine\/nab-paclitaxel for the treatment of metastatic pancreas cancer: interim analysis","author":"Bahary","year":"2016","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.actbio.2019.03.048_b0145","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.3026","article-title":"A phase I study of indoximod in combination with docetaxel in metastatic solid tumors","author":"Jackson","year":"2013","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.actbio.2019.03.048_b0150","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.3069","article-title":"A phase I study of Ad. p53 DC vaccine in combination with indoximod in metastatic solid tumors","author":"Soliman","year":"2013","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.actbio.2019.03.048_b0155","article-title":"A phase 2 study of docetaxel in combination with indoximod in metastatic breast cancer","author":"Soliman","year":"2014","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.actbio.2019.03.048_b0160","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.tps2107","article-title":"A phase I\/II study of the combination of indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors","author":"Zakharia","year":"2014","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.actbio.2019.03.048_b0165","article-title":"Abstract CT117: interim analysis of the phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma","author":"Zakharia","year":"2017","journal-title":"AACR"},{"key":"10.1016\/j.actbio.2019.03.048_b0170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2017.09.004","article-title":"A combination of nanosystems for the delivery of cancer chemoimmunotherapeutic combinations: 1-Methyltryptophan nanocrystals and paclitaxel nanoparticles","volume":"126","author":"Calleja","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.actbio.2019.03.048_b0175","article-title":"A novel prodrug of indoximod with enhanced pharmacokinetic properties","author":"Mautino","year":"2017","journal-title":"AACR"},{"key":"10.1016\/j.actbio.2019.03.048_b0180","article-title":"Salts and prodrugs of 1-methyl-d-tryptophan","author":"Mautino","year":"2017","journal-title":"Google Patents"},{"issue":"1","key":"10.1016\/j.actbio.2019.03.048_b0185","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41467-017-01651-9","article-title":"Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression","volume":"8","author":"Lu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2019.03.048_b0190","article-title":"Injectable bioresponsive gel depot for enhanced immune checkpoint blockade","volume":"1801527","author":"Yu","year":"2018","journal-title":"Adv. Mater."},{"issue":"5\u20136","key":"10.1016\/j.actbio.2019.03.048_b0195","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1080\/1061186X.2017.1419355","article-title":"Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs","volume":"26","author":"Xu","year":"2018","journal-title":"J. Drug Target."},{"key":"10.1016\/j.actbio.2019.03.048_b0200","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biomaterials.2016.09.001","article-title":"Development of a multi-target peptide for potentiating chemotherapy by modulating tumor microenvironment","volume":"108","author":"Song","year":"2016","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.actbio.2019.03.048_b0205","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.bmc.2015.08.016","article-title":"C ring may be dispensable for \u03b2-carboline: design, synthesis, and bioactivities evaluation of tryptophan analog derivatives based on the biosynthesis of \u03b2-carboline alkaloids","volume":"24","author":"Huang","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"1\u20132","key":"10.1016\/j.actbio.2019.03.048_b0210","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0168-3659(00)00340-0","article-title":"Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA\u2013PEG block copolymer","volume":"70","author":"Yoo","year":"2001","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.actbio.2019.03.048_b0215","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijpharm.2013.06.017","article-title":"Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment","volume":"454","author":"Duong","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.actbio.2019.03.048_b0220","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jconrel.2004.12.018","article-title":"Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor","volume":"103","author":"Lee","year":"2005","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.actbio.2019.03.048_b0225","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1021\/acs.chemrestox.8b00023","article-title":"Identification of novel pathways in idelalisib metabolism and bioactivation","volume":"31","author":"Zhu","year":"2018","journal-title":"Chem. Res. Toxicol."},{"issue":"10","key":"10.1016\/j.actbio.2019.03.048_b0230","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11095-018-2480-8","article-title":"Hyaluronic acid layer-by-layer (LbL) nanoparticles for synergistic chemo-phototherapy","volume":"35","author":"Zhao","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.actbio.2019.03.048_b0235","article-title":"A reversible decomposition approach for the formation of injectable, excipient-free, self-assembling nanocrystals","author":"Yang","year":"2019","journal-title":"Chem. Commun."},{"issue":"11","key":"10.1016\/j.actbio.2019.03.048_b0240","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1021\/acs.molpharmaceut.5b00536","article-title":"Co-delivery of pirarubicin and paclitaxel by human serum albumin nanoparticles to enhance antitumor effect and reduce systemic toxicity in breast cancers","volume":"12","author":"Yi","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.actbio.2019.03.048_b0245","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jconrel.2017.12.026","article-title":"Enhanced antitumor and anti-metastasis efficacy against aggressive breast cancer with a fibronectin-targeting liposomal doxorubicin","volume":"271","author":"Jiang","year":"2018","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.actbio.2019.03.048_b0250","first-page":"1369","article-title":"A submicron emulsion for intravenous injection of 7-ethyl-10-hydroxycamptothecin: characterization, pharmacolcinetic and biodistribution studies, in vitro and in vivo antitumor effect","volume":"35","author":"Song","year":"2016","journal-title":"Lat. Am. J. Pharm."},{"key":"10.1016\/j.actbio.2019.03.048_b0255","series-title":"Tunable Immunostimulatory Nanocarrier For Improving Cancer Immunochemotherapy","author":"Wan","year":"2017"},{"issue":"47","key":"10.1016\/j.actbio.2019.03.048_b0260","doi-asserted-by":"crossref","first-page":"14854","DOI":"10.1021\/jacs.5b10182","article-title":"A Pt (IV) pro-drug preferentially targets indoleamine-2, 3-dioxygenase, providing enhanced ovarian cancer immuno-chemotherapy","volume":"137","author":"Awuah","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.actbio.2019.03.048_b0265","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.actbio.2016.07.014","article-title":"A prodrug micellar carrier assembled from polymers with pendant farnesyl thiosalicylic acid moieties for improved delivery of paclitaxel","volume":"43","author":"Sun","year":"2016","journal-title":"Acta Biomater."},{"issue":"12","key":"10.1016\/j.actbio.2019.03.048_b0270","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/adhm.201400455","article-title":"\u03c0\u2013\u03c0 stacking induced enhanced molecular solubilization, singlet oxygen production, and retention of a photosensitizer loaded in thermosensitive polymeric micelles","volume":"3","author":"Shi","year":"2014","journal-title":"Adv. Healthcare Mater."},{"issue":"6","key":"10.1016\/j.actbio.2019.03.048_b0275","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/acsbiomaterials.5b00006","article-title":"Interfacially hydrazone cross-linked thermosensitive polymeric micelles for acid-triggered release of paclitaxel","volume":"1","author":"Shi","year":"2015","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"1","key":"10.1016\/j.actbio.2019.03.048_b0280","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2019.03.048_b0285","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jconrel.2016.11.013","article-title":"Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment","volume":"245","author":"Huo","year":"2017","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.actbio.2019.03.048_b0290","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1080\/03639045.2018.1506475","article-title":"A novel honokiol liposome: formulation, pharmacokinetics, and antitumor studies","volume":"44","author":"Zhou","year":"2018","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"7","key":"10.1016\/j.actbio.2019.03.048_b0295","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd1775","article-title":"Design and development of polymers for gene delivery","volume":"4","author":"Pack","year":"2005","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"3","key":"10.1016\/j.actbio.2019.03.048_b0300","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1021\/nn102711d","article-title":"Multifunctional triblock nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing","volume":"5","author":"Patil","year":"2011","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.actbio.2019.03.048_b0305","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1517\/17425255.2011.548805","article-title":"Role of phosphatidylserine binding in tissue distribution of amine-containing basic compounds","volume":"7","author":"Murakami","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"13","key":"10.1016\/j.actbio.2019.03.048_b0310","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1016\/S0021-9258(17)38501-0","article-title":"Lung lamellar bodies maintain an acidic internal pH","volume":"261","author":"Chander","year":"1986","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.actbio.2019.03.048_b0315","doi-asserted-by":"crossref","first-page":"1801012","DOI":"10.1002\/advs.201801012","article-title":"Deep tumor-penetrated nanocages improve accessibility to cancer stem cells for photothermal-chemotherapy of breast cancer metastasis","volume":"5","author":"Tan","year":"2018","journal-title":"Adv. Sci."},{"issue":"9","key":"10.1016\/j.actbio.2019.03.048_b0320","doi-asserted-by":"crossref","first-page":"7821","DOI":"10.1021\/acsami.7b19183","article-title":"Enhanced chemotherapeutic efficacy of paclitaxel nanoparticles co-delivered with microrna-7 by inhibiting paclitaxel-induced EGFR\/ERK pathway activation for ovarian cancer therapy","volume":"10","author":"Cui","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2019.03.048_b0325","article-title":"Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment","volume":"1803001","author":"Feng","year":"2018","journal-title":"Adv. Mater."},{"issue":"3","key":"10.1016\/j.actbio.2019.03.048_b0330","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706119302235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706119302235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:15:04Z","timestamp":1761671704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706119302235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":66,"alternative-id":["S1742706119302235"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2019.03.048","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2019.03.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}